FDA Extends Review of Somaxon Pharmaceuticals' New Drug Application for Silenor (Doxepin).
HEALTH AND BEAUTY CLOSE-UP-29 November 2008-FDA Extends Review of Somaxon Pharmaceuticals' New Drug Application for Silenor (Doxepin)(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the...

TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia.
LA JOLLA, Calif., Dec. 2 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced positive results from a 26 patient Phase II trial evaluating three doses of NGX267 as a treatment for xerostomia, or dry mouth, in patients with Sjogren's syndrome. NGX267 met the primary endpoint of a statistically significant increase...

Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors.
MIAMI, Nov. 26 /PRNewswire/ -- Thomas K. Equels, President and Managing Director of the Equels Law Firm, has been elected to the board of directors for Hemispherx BioPharma, Inc. , a Philadelphia-based biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for the treatment of...

ev3 Inc. Appoints John L. Miclot to Board of Directors.
PLYMOUTH, Minn., Dec. 3 /PRNewswire-FirstCall/ -- ev3 Inc. , a global endovascular device company, today announced the appointment of John L. Miclot to its Board of Directors effective immediately. Mr. Miclot is currently the president and chief executive officer of CCS Medical, a privately held nationwide provider...

TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel.
LA JOLLA, Calif., Nov. 25 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced that it has purchased from Eli Lilly & Company a reduction in certain royalty amounts that may become payable to Eli Lilly on net sales of TorreyPines' clinical-stage compounds NGX426 and tezampanel, should either or both gain...

Allos Therapeutics Gets FDA Pralatrexate Orphan Drug Designation.
HEALTH AND BEAUTY CLOSE-UP-4 December 2008-Allos Therapeutics Gets FDA Pralatrexate Orphan Drug Designation(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Allos Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, announced that the U.S. Food and Drug Administration (FDA)...

Somaxon Pharmaceuticals Posts 2008 3Q Financial Results.
HEALTH AND BEAUTY CLOSE-UP-12 November 2008-Somaxon Pharmaceuticals Posts 2008 3Q Financial Results(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Somaxon Pharmaceuticals, a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology, announced...

Sequenom Reports Data from Collaborative Project with The Chinese University of Hong Kong.
HEALTH AND BEAUTY CLOSE-UP-27 November 2008-Sequenom Reports Data from Collaborative Project with The Chinese University of Hong Kong(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Sequenom, announced that advanced data from a collaborative project with The Chinese University of Hong Kong, supporting the noninvasive prenatal diagnosis of monogenic diseases, were...

Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology.
Results from Phase II Trial of DU-176b in Atrial Fibrillation Included in Scientific Program EDISON, N.J., Dec. 2 /PRNewswire/ -- Daiichi Sankyo, Inc. , today announced that results from three studies of its investigational molecule, DU-176b, will be presented at the 50th Annual Meeting of the American...

TorreyPines Therapeutics Licenses Posiphen(TM), Bisnorcymcerine and Phenserine to QR Pharma.
LA JOLLA, Calif., Nov. 18 /PRNewswire/ -- TorreyPines Therapeutics, Inc. today announced that it has licensed to QR Pharma, Inc. the worldwide rights to Posiphen(TM), bisnorcymcerine and phenserine. QR Pharma is an emerging biotechnology company focusing on the development of compounds to treat Alzheimer's disease and other cognitive disorders....